BioSpace News Archive

Scientists from different agencies and research facilities have turned to laboratory manufactured human mini-brains to study the onset and progression of Parkinson’s disease.

Chin, 57, and Humad, 36, along with the company, were indicted on charges of paying surgeons to use their spinal implants in surgeries.

The acquisition expands Sanofi’s General Medicines core assets and highlights the addition of Rezurock (belumosudil) to its transplant portfolio.

Attralus Therapeutics has had a fresh set of faces shuffling into its executive suite in the past few months. And apparently with new leadership comes new funding opportunities.

Medical device reprocessing can be defined as cleaning, sterilizing, repairing, refurbishing, disinfecting, and reconditioning of the used medical devices.

The latest Fact.MR research study offers oral antivirals demand outlook and studies growth opportunities in key segments, including type, drug class, disease indication, and distribution channel.

Oxurion NV, a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with a clinical stage portfolio in vascular retinal disorders, will be presenting preclinical and clinical data from its ongoing development programs, THR-149 and THR-687 as novel treatments for diabetic macular edema at the EURETINA 2021 Virtual congress.

AM-Pharma B.V., an emerging leader focused on developing therapeutics for severe medical conditions, and Kyowa Kirin Co., Ltd., a global specialty pharmaceutical company that strives to create new value through the pursuit of advances in life sciences and technologies, announced that they have entered into an exclusive license agreement under which Kyowa Kirin gains the rights to develop and commercialize ilofotase alfa, AM-Pharma’s proprietary recombinant human alkaline phosphatase.

EdiGene, Inc., announced the first patient enrolled in multicenter Phase I clinical study of its investigational gene-editing hematopoietic stem cell therapy ET-01 for patients with transfusion dependent β-thalassemia at the Institute of Hematology and Blood Diseases Hospital, CAMS & PUMC, and activation of the investigational site at Nanfang Hospital of Southern Medical University in Guangzhou, Guangdong Province.

Design Therapeutics, Inc., a biotechnology company developing small molecule treatments for degenerative genetic disorders, announced new preclinical data from its novel DM1 GeneTAC™ program, which demonstrated a near-complete resolution of disease-causing foci and correction of splicing defects in myotonic dystrophy type-1 patient cells.